(Q34343267)

1 August 2017

1 reference

title

Synthetic biomimetic supra molecular Biovector (SMBV) particles for nasal vaccine delivery (English)

1 reference

1 August 2017

0 references

von Hoegen P

1

1 reference

PubMed ID

11516783

1 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

Advanced Drug Delivery Reviews

1 August 2017

1 reference

1 August 2017

51

1 reference

1 August 2017

1-3

1 reference

1 August 2017

113-125

1 reference

Adjuvants for human vaccines--current status, problems and future prospects

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Characterisation and phase behaviour of phospholipid bilayers adsorbed on spherical polysaccharidic nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Structural characterization (shape and dimensions) and stability of polysaccharide/lipid nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Structural characterization of organized systems of polysaccharides and phospholipids by light scattering spectroscopy and electron microscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

A new family of carriers (biovectors) enhances the immunogenicity of rabies antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Humoral and cell-mediated immunity to vero cell-derived influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Screening of cationic compounds as an absorption enhancer for nasal drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Chitosan as a novel nasal delivery system for peptide drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

A novel bioadhesive intranasal delivery system for inactivated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Combination of human cytomegalovirus recombinant immediate-early protein (IE1) with 80 nm cationic biovectors: protection from proteolysis and potentiation of presentation to CD4+ T-cell clones in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Intranasal immunization against influenza virus using polymeric particles

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Comparison of in vitro immunostimulatory potential of live and inactivated influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8(+) cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular Bio Vector (SMBV).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900175-2

7 January 2021

10.1016/S0169-409X(01)00175-2

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11516783